Document is current

Any future updates will be listed below

Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors

Crossref DOI link: https://doi.org/10.1007/s00280-014-2521-x

Published Online: 2014-07-25

Published Print: 2014-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark